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Abstract: 
Gynacomastia is a rare condition in males with a symptom of enlarged breast tissue size. It is generally caused by 
altered ratio of estrogens to androgens in the male individuals. A cause includes several diseases and nearly25% is 
associate with drugs. A mostly used drug that causes gynacomastia includes spironolactone, amlodepine, TCAs, and 
ketoconazole. It is a rare side effect. But it has a occurrence of 1% in amlodepine and 1.2% in spironolactone. 
Diagnosis is majorly done by presence of symptoms like increased  breast tissue, and it should be differentiate with 
pseudo disease, and the increasing nature may be of one side or on both side of individuals. Presence of polactin 
secreting tumor may induce milk ejection from male breasts. Mostly it is resolved with in one to two months of 
discontinuation of suspected drug. Mastectomy is the only surgical procedure where the increased breast tissue is 
removed. Drugs like aromatase inhibitors, estrogen receptor modulators can also be used, but has no clinical 
practice in males. 
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INTRODUCTION: 
Gynacomastia is a rare endocrine disorder having an 
increased size of breast tissue in males [1]. Mostly it 
is caused by klinfonter syndrome, cancers, endocrine 
disorder, metabolic dysfunction, and some medicines 
[2].Sometimes it is also associated with diseased 
state. A study states that nearly 70% of adolescent 
boys are affected [4] and 75 among them are self 
resolved without any medication within a span of 2 
years [3]. 
 
An ADR can be defined as a noxious or unintended 
reaction that occurs at a normal dose i.e., used for 
diagnosis, prevention or for a treatment. 
Gynacomastia is a result of altered estrogen and 
androgen ratio in males [4]. Estrogens act as a 
hormone in increasing the size of male breast tissue 
[5]. Most of the causes are unknown6 bur drugs are a 
cause in 10-25% of patients with gynacomastia [7]. 
 
                                                  Table 1: List of some of the drugs that cause gynacomastia 
Antiandrogens Bicalutamide, flutamide, finasteride, dutasteride 
Antihypertensive     Spironolactone 
Antiretroviral 
Protease inhibitors (saquinavir, indinavir, nelfinavir, ritonavir, lopinavir), 
reverse transcriptase inhibitors (stavudine, zidovudine, lamivudine) 
Environmental exposure Phenothrin (antiparasitical) 
Exogenous hormones Oestrogens, prednisone (male teenagers) 
Gastrointestinal drugs H2 histamine receptor blockers (cimetidine) 
Antifungal Ketoconazole (prolonged oral use) 
Antihypertensive 
Calcium channel blockers (amlodipine, diltiazem, felodipine, nifedipine, 
verapamil),  diuretics (spironolactone). 
Antipsychotic                  (first 
generation) 
Haloperidol, olanzapine, paliperidone (high doses), risperidone (high doses), 
ziprasidone 
 
 
 
Typical symptoms include breast enlargement with 
soft, subcutaneous chest palpated in soft fatty tissue 
[8] and may be on one side or both [6]. Individual 
with prolactin secreting tumor may have a symptom 
of milk secretion [4]. Patient may also feel anxious 
and stress [5]. 
 
Diagnosis of gynacomastia is generally a subjective. 
But a physician should rule out pseudogyancomastia 
may be of a fatty tissue4. Generally it is divided into 4 
grades: 
 Grade I: Minor enlargement, no skin excess 
 Grade II: Moderate enlargement, no skin 
excess 
 Grade III: Moderate enlargement, skin 
excess 
 Grade IV: Marked enlargement, skin excess 
[9]. 
Treatment generally includes the use of aromatase 
inhibitors, estrogen receptor modulators [10] and 
May involves surgery like mastectomy [9]. 
Amlodepine is a calcium channel blocker used for 
treatment of hypertension. It causes gynacomastia in 
0.1-1% of treated individuals [11]. The exact 
mechanism of gynacomastia is unclear in calcium 
antagonists [12].  Spironolactone induces 
gynecomastia by decreasing testosterone production, 
increasing peripheral conversion of testosterone to 
estradiol, and displacing estradiol from sex hormone-
binding globulin [13].  The Boston Collaborative 
Drug Surveillance Program reported a 1.2% 
prevalence of gynecomastia among 164 hospitalized 
patients (20.8%) experiencing adverse events (out of 
788) treated with spironolactone [14].. 
Here we present a case report on gynacomastia 
induced by amlodepine and spironolactone. 
CASE REPORT; 
A 39 years male patient was admitted in general 
surgery Dept. with chief complaints of swelling over 
right breast since 15 days, swelling with small in size 
before 2 months and gradually attained this size. He 
was a known hypertensive since 2 years under 
regular treatment with T. amlodepine 5mg od, T. 
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atorvastatin of 10mg od, T. pantop of 40mg od. At 
the time of diagnosis he had BP of 160/100 mmhg. 
Since 3 months he had complained of edema of legs. 
So he was treated with same medication along with 
T. lasix of 20mg and spironolactone of 25mg once 
daily. He was a mixed diet habitat, alcoholic and non 
smoker. Now he had BP of 130/90 mmhg, and all 
other vitals and lab findings were normal. He was 
diagnosed as drug induced gynacomastia and he was 
advised with mastectomy. After the day of surgery he 
was treated with in. ceftriaxone of 1gm bd, inj. 
Diclofenac of 75mg bd, inj. Rantac of 50mg bd. 
After 6 days he was treated with same medication 
and on seventh day he was discharged with T. 
cefixime of 200mg bd, tab. diclofenac of 50mg bd, 
and t. rantac of 150mg. 
 
ADR ANALYSIS: 
Casuality: 
WHO-UMC: probable 
Naranjos assessment: possible 
Severity assessment: level 4(b) moderate. 
Predicatability: type A reaction. 
Preventability: moderately preventable.  
 
CONCLUSION:  
This case highlights that anti hypertensive treatment 
including calcium channel blockers, spironolactone 
may lead to rare effect of gynacomastia. Therefore, 
physicians should carefully observe patients and 
discontinue causative agents if any symptoms are 
observed. This case highlights the rare chances of 
occurrence of adverse reactions to the drugs, so a 
physician should monitor the individual throughout a 
therapy. 
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